Pharming Group NV

Pharming Group has a market capitalization of $926.2 million, with a current market price of $13.2 per share. The company has 70.17 million shares outstanding, with no dilution from potential share issuance as of the latest data. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. The company's profitability and returns are not currently available in the valuation snapshot, and no industry_config preferred metrics are provided for comparison. This lack of data limits the ability to assess Pharming Group's performance relative to its peers in the biotechnology and pharmaceuticals sectors. Pharming Group's revenue concentration and geographic exposure are not disclosed in the available data. The company operates in the global biopharmaceutical market, but specific segment or regional breakdowns are not provided in the input data. The company's growth trajectory is not quantified in the input data, and no numeric deltas are provided for the current or next fiscal year. Analysts have issued a mean price target of $2.21, with a median of $2.23, indicating a significant downside from the current market price. Risk factors include the inability to assess liquidity risk and the absence of detailed financial disclosures. The company has a low dilution risk, but the lack of balance-sheet data raises concerns about its financial stability. No recent events, such as filings or transcripts, are provided in the input data to inform on near-term developments. No recent events, such as filings or transcripts, are provided in the input data to inform on near-term developments.